ProPhase Labs (NASDAQ:PRPH – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $3.77 million for the quarter.
ProPhase Labs Stock Down 3.0 %
PRPH opened at $0.37 on Wednesday. The firm has a 50 day moving average price of $0.49 and a 200 day moving average price of $1.28. The company has a market cap of $8.81 million, a PE ratio of -0.29 and a beta of -0.53. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on shares of ProPhase Labs in a research report on Tuesday, February 25th. They set a “sell” rating for the company.
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Further Reading
- Five stocks we like better than ProPhase Labs
- How to Use the MarketBeat Excel Dividend Calculator
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What Are the U.K. Market Holidays? How to Invest and Trade
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What Are Trending Stocks? Trending Stocks Explained
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
